Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
Status:
Recruiting
Trial end date:
2023-06-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to provide safety and tolerability, pharmacokinetics and
immunogenicity data for multiple CSJ117 doses inhaled once daily compared with placebo, in
adult asthma participants treated with medium or high dose ICS plus LABA alone or with
additional asthma controllers (additional controllers allowed: LTRA, LAMA, Theophylline and
its derivatives), who have completed the prior phase llb study CCSJ117A12201C (NCT04410523).